These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32875989)

  • 1. Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial.
    Jiang J; Lin L; Chen P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1366-1374. PubMed ID: 32875989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
    Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
    J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.
    Hiramatsu T; Ito H; Okumura S; Asano Y; Iguchi D; Furuta S
    Diab Vasc Dis Res; 2020; 17(6):1479164120971220. PubMed ID: 33371732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.
    Gorgojo-Martínez JJ; Serrano-Moreno C; Sanz-Velasco A; Feo-Ortega G; Almodóvar-Ruiz F
    Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):129-137. PubMed ID: 28077257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
    J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial.
    Sposito AC; Breder I; Soares AAS; Kimura-Medorima ST; Munhoz DB; Cintra RMR; Bonilha I; Oliveira DC; Breder JC; Cavalcante P; Moreira C; Moura FA; de Lima-Junior JC; do Carmo HRP; Barreto J; Nadruz W; Carvalho LSF; Quinaglia T;
    Cardiovasc Diabetol; 2021 Mar; 20(1):74. PubMed ID: 33771149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
    Shigiyama F; Kumashiro N; Fuchigami A; Hirose T
    Cardiovasc Diabetol; 2018 Jun; 17(1):86. PubMed ID: 29895330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Efficacy and Safety of Liraglutide and Dapagliflozin on Glucose and Lipid Metabolism and Insulin Function in Patients with Type 2 Diabetes Mellitus.
    Ma J; Fu J; Guo N; Liu Z
    Altern Ther Health Med; 2024 Aug; 30(8):144-151. PubMed ID: 38294744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.
    Lim S; Lee SH; Min KW; Lee CB; Kim SY; Yoo HJ; Kim NH; Kim JH; Oh S; Won JC; Kwon HS; Kim MK; Park JH; Jeong IK; Kim S
    Diabetes Obes Metab; 2024 Jun; 26(6):2188-2198. PubMed ID: 38425186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study.
    Phrommintikul A; Wongcharoen W; Kumfu S; Jaiwongkam T; Gunaparn S; Chattipakorn S; Chattipakorn N
    Br J Clin Pharmacol; 2019 Jun; 85(6):1337-1347. PubMed ID: 30767253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
    Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
    Bonora BM; Vigili de Kreutzenberg S; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2019 Aug; 18(1):106. PubMed ID: 31412874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China.
    Zhaohu H; Xiao H; Hailin S; Feng H
    J Diabetes Res; 2022; 2022():4126995. PubMed ID: 35990242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
    Gessner A; Gemeinhardt A; Bosch A; Kannenkeril D; Staerk C; Mayr A; Fromm MF; Schmieder RE; Maas R
    Cardiovasc Diabetol; 2022 Jan; 21(1):4. PubMed ID: 34991562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
    Fadini GP; Sciannameo V; Franzetti I; Bottigliengo D; D'Angelo P; Vinci C; Berchialla P; Arena S; Buzzetti R; Avogaro A;
    Diabetes Obes Metab; 2019 Aug; 21(8):1886-1894. PubMed ID: 30985052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.
    Petrykiv S; Sjöström CD; Greasley PJ; Xu J; Persson F; Heerspink HJL
    Clin J Am Soc Nephrol; 2017 May; 12(5):751-759. PubMed ID: 28302903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
    Dekkers CCJ; Wheeler DC; Sjöström CD; Stefansson BV; Cain V; Heerspink HJL
    Nephrol Dial Transplant; 2018 Nov; 33(11):2005-2011. PubMed ID: 29370424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.
    Fadini GP; Zatti G; Baldi I; Bottigliengo D; Consoli A; Giaccari A; Sesti G; Avogaro A;
    Diabetes Obes Metab; 2018 Jul; 20(7):1781-1786. PubMed ID: 29516612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.